Nucleome was founded in 2019. The precision of its 3D genomics technology has the potential to improve drug discovery success rates both by discovering genetically-validated medicines, and by more accurately identifying patients who are likely to benefit from treatments. Nucleome’s platform can be applied to multiple disease indications and cell types, with an initial focus on inflammatory conditions. In addition to building its own pipeline, the company is forging external collaborations in target discovery, target validation, and patient stratification.
Nucleome was founded by leading experts in gene regulation from the University of Oxford. The Company is backed by a world-class syndicate of investors that includes M Ventures, the strategic corporate venture capital arm of Merck KGaA; Johnson and Johnson Innovation-JJDC, Inc. (“JJDC”), the strategic venture capital arm of Johnson & Johnson; Pfizer Ventures, the venture group of Pfizer; British Patient Capital; and founding investor Oxford Science Enterprises.
Company Details
- Employees
- 57
- Founded
- 2019
- Address
- Oxford, Gb
- in****@****ome.com
- Industry
- Biotechnology
- Website
- nucleome.com
- HQ
- Oxford
Nucleome Therapeutics Questions
Nucleome Therapeutics's website is nucleome.com
Nucleome Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/nucleome-therapeutics
Nucleome Therapeutics has
57 employees.
View email and phone details for 57
employees at Nucleome Therapeutics.
Nucleome Therapeutics's industry is
Biotechnology
Nucleome Therapeutics's top competitors are
Theolytics,
Oxb,
Sitryx,
Immunocore,
Ochre Bio,
Evox Therapeutics Ltd,
Quell Therapeutics,
Omass Therapeutics,
Enara Bio,
Rome Therapeutics.
Nucleome Therapeutics's support email address is info@nucleome.com
Nucleome Therapeutics's categories are Biotechnology
Nucleome Therapeutics's founding year is 2019
